Centre for Children's Health Research, Children's Health Queensland, Brisbane, Australia.
Child Health Research Centre, The University of Queensland, Brisbane, Australia.
Malar J. 2021 Apr 10;20(1):181. doi: 10.1186/s12936-021-03717-y.
Volunteer infection studies have become a standard model for evaluating drug efficacy against Plasmodium infections. Molecular techniques such as qPCR are used in these studies due to their ability to provide robust and accurate estimates of parasitaemia at increased sensitivity compared to microscopy. The validity and reliability of assays need to be ensured when used to evaluate the efficacy of candidate drugs in clinical trials.
A previously described 18S rRNA gene qPCR assay for quantifying Plasmodium falciparum in blood samples was evaluated. Assay performance characteristics including analytical sensitivity, reportable range, precision, accuracy and specificity were assessed using experimental data and data compiled from phase 1 volunteer infection studies conducted between 2013 and 2019. Guidelines for validation of laboratory-developed molecular assays were followed.
The reportable range was 1.50 to 6.50 log parasites/mL with a limit of detection of 2.045 log parasites/mL of whole blood based on a parasite diluted standard series over this range. The assay was highly reproducible with minimal intra-assay (SD = 0.456 quantification cycle (C) units [0.137 log parasites/mL] over 21 replicates) and inter-assay (SD = 0.604 C units [0.182 log parasites/mL] over 786 qPCR runs) variability. Through an external quality assurance program, the QIMR assay was shown to generate accurate results (quantitative bias + 0.019 log parasites/mL against nominal values). Specificity was 100% after assessing 164 parasite-free human blood samples.
The 18S rRNA gene qPCR assay is specific and highly reproducible and can provide reliable and accurate parasite quantification. The assay is considered fit for use in evaluating drug efficacy in malaria clinical trials.
志愿者感染研究已成为评估抗疟药物疗效的标准模型。在这些研究中,由于 qPCR 等分子技术能够提供比显微镜更灵敏的寄生虫血症的稳健和准确估计,因此被用于提供比显微镜更灵敏的寄生虫血症的稳健和准确估计。在临床试验中评估候选药物的疗效时,需要确保检测方法的有效性和可靠性。
评估了一种以前描述的用于定量血液样本中疟原虫 falciparum 的 18S rRNA 基因 qPCR 检测方法。使用实验数据和 2013 年至 2019 年期间进行的 1 期志愿者感染研究中汇编的数据评估了检测方法的性能特征,包括分析灵敏度、报告范围、精密度、准确性和特异性。遵循了实验室开发的分子检测方法验证指南。
报告范围为 1.50 至 6.50 log 寄生虫/mL,基于在此范围内稀释的寄生虫标准系列,检测限为 2.045 log 寄生虫/mL 的全血。该检测方法具有高度可重复性,最小的内检测变异性(21 个重复的 SD=0.456 定量循环(C)单位[0.137 log 寄生虫/mL])和外检测变异性(786 个 qPCR 运行的 SD=0.604 C 单位[0.182 log 寄生虫/mL])。通过外部质量保证计划,证明 QIMR 检测方法能够生成准确的结果(相对于标称值的定量偏差+0.019 log 寄生虫/mL)。在评估了 164 份无寄生虫的人类血液样本后,特异性为 100%。
18S rRNA 基因 qPCR 检测方法具有特异性和高度可重复性,能够提供可靠和准确的寄生虫定量。该检测方法被认为适合用于评估疟疾临床试验中的药物疗效。